Compare GENC & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GENC | DRUG |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | 25 |
| Industry | Construction/Ag Equipment/Trucks | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.2M | 228.0M |
| IPO Year | 1995 | 2020 |
| Metric | GENC | DRUG |
|---|---|---|
| Price | $17.50 | $22.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $21.00 | ★ $107.21 |
| AVG Volume (30 Days) | 32.5K | ★ 255.8K |
| Earning Date | 12-08-2026 | 08-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.08 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $48,943,000.00 | N/A |
| Revenue This Year | $1.78 | N/A |
| Revenue Next Year | $25.68 | N/A |
| P/E Ratio | $19.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.22 | $17.40 |
| 52 Week High | $20.19 | $123.75 |
| Indicator | GENC | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 27.92 |
| Support Level | $16.75 | $17.40 |
| Resistance Level | $18.11 | $58.93 |
| Average True Range (ATR) | 0.55 | 3.55 |
| MACD | 0.05 | -1.19 |
| Stochastic Oscillator | 70.15 | 13.22 |
Gencor Industries Inc and its subsidiaries are a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company's products are manufactured in the United States and sold through a combination of Company sales representatives and independent dealers and agents. The Company has one reporting segment, equipment for the highway construction industry. The Company's principal core products include asphalt pavers, hot mix asphalt plants, combustion systems, and fluid heat transfer systems. It operates in the United States, Canada, and other foreign countries, with the majority of revenue coming from the United States.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.